期刊文献+

基质金属蛋白酶MMP-9及其组织抑制剂TIMP-1mRNA在卵巢上皮性肿瘤中的表达及其临床意义(英文) 被引量:2

Expression of MMP-9 and TIMP-1 in epithelial ovarian tumors and their clinical significance
下载PDF
导出
摘要 目的探讨基质金属蛋白酶(MMP-9)及其组织抑制物(TIMP-1)mRNA与卵巢上皮性癌的发生、发展的关系。方法采用RT-PCR技术检测69例卵巢上皮性肿瘤(38例恶性、15例交界性、16例良性)及11例正常卵巢组织中MMP-9及TIMP-1mRNA的表达,并分析其与各临床病理特征的关系。结果MMP-9mRNA在卵巢上皮性癌及交界性肿瘤组织中的阳性表达率(分别为76%、44%)及表达水平[分别为(154.14±4.42)、(96.87±3.04)]均显著高于良性肿瘤及正常卵巢组织[分别为13%、9%和(8.26±2.67)、(2.34±1.02);P<0.05];且MMP-9mRNA在晚期卵巢上皮性癌组织中的阳性表达率和表达水平明显高于早期癌组织(P<0.05)。TIMP-1mRNA在卵巢上皮性癌及交界性肿瘤组织中的阳性表达率(分别为68%、38%)及表达水平[分别为(126.35±3.81)、(90.62±5.54)]均显著高于良性肿瘤及正常卵巢组织[分别为13%、9%和(8.32±2.02)、(2.63±1.35);P<0.05];TIMP-1mRNA在卵巢上皮性癌组织中的阳性表达率和表达水平与各临床病理特征均无相关性(P>0.05)。结论MMP-9mRNA的高表达及MMP-9/TIMP-1平衡的调节失衡导致卵巢上皮性肿瘤的发生、侵袭和转移;MMP-9mRNA的高表达对卵巢上皮性癌有预后意义。 [Objective] To investigate the correlations of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) mRNA with tumorigenesis and progression of epithelial ovarian carcinoma (EOC). [Methods] Reverse transcriptase polymerase chain reaction (RT-PCR) was performed to evaluate mRNA expression of MMP- 9 and TIMP- 1 in 69 cases of epithelial ovarian neoplasm (38 malignant, 15 borderline and 16 benign) as well as 11 cases of normal ovarian tissues, and explore their correlations with clinieopathologic characteristics. [Results] The positive rates (76%, 44%, respectively) and semiquantitative levels [(154.14±4.42), (96.87±3.04), respectively] of MMP- 9 mRNA expression were significantly higher in EOC and borderline tumors than those in benign tumors and normal ovarian tissues [13%, 9%, respectively; and (8.26±2.67), (2.34±1.02), respectively, P 〈 0.05]. The expression level of MMP- 9 mRNA in advanced stage EOC was significantly higher than that in early stage EOC (P 〈0.05). The positive rate (68%, 38%, respectively) and semi-quantitative level [(126.35±3.81), (90.62± 5.54), respectively] of TIMP-1 mRNA were significantly higher in EOC and borderline tumors than those in benign tumors and normal ovarian tissues [13%, 9% and (8.32±2.02), (2.63±1.35), respectively; P 〈0.05]. No correlations were found in positive rate and semi-quantitative level of TIMP-1 mRNA expression with clinicopathologie characteristics in EOC. [Conclusions] The overexpression of MMP-9 mRNA and the imbalance between MMP- 9 and TIMP- 1 may lead to tumorigenesis, invasion and metastasis in epithelial ovarian tumor. Overexpression of MMP- 9 mRNA may have prognostic significance in EOC.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2009年第8期1121-1125,1133,共6页 China Journal of Modern Medicine
关键词 卵巢肿瘤 基质金属蛋白酶-9 基质金属蛋白酶组织抑制物-1 侵袭 RT—PCR ovarian neoplasm MMP-9 TIMP-1 invasion RT-PCR
  • 相关文献

参考文献16

  • 1CURRAN S, MURRAY GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis[J]. Eur J Cancer, 2000, 36: 1621-1630.
  • 2CURRAN S, MURRAY GI. Matrix metalloproteinases in tumour invasion and metastasis[J]. J Pathol, 1999, 189(3): 300-308.
  • 3LAMBERT E, DASSE E, HAYE B, et al. TIMPs as muhifacial proteins[J]. Crit Rev Oncol Hematol, 2004, 49: 187-198.
  • 4SILLANPAA S, ANTrILA M, VOUTILAINEN K, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer[J]. Gynecol Oncol, 2007, 104(2): 295-303.
  • 5CAI KQ, YANG WL CAPO-CHICHI CD, et al. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis[J]. Mol Carcinog, 2007, 46(2): 130-143.
  • 6HU XX, LI LI, LI DR, et al. Expression and clinical significance of MMP-9, 2, 7and their inhibitors TIMP-1, 2, 3 in ovarian tumors[J]. Cancer, 2004, 23(10): 1194-1198.
  • 7RAUVALA M, PUISTOLA U, TURPEENNIEMI-HUJANEN T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor[J]. Gynecol Oncol, 2005, 99(3): 656-663.
  • 8SAKATA K, SHIGEMASA K, NAGAI N, et al. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary[J]. Int J Oncol, 2000, 17(4): 673-681.
  • 9HUANG L-W, GARRETT AP, Bell DA, et al. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors [J]. Gyneeol Oneol, 2000, 77: 369-376.
  • 10CAPO-CHICHI CD, SMITH ER, YANG DH, et al. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis [J]. Cancer, 2002, 95(8): 1802-1815.

同被引文献28

  • 1魏莉,徐盈.基质金属蛋白酶9在老年肺癌中的表达及临床意义[J].中国老年学杂志,2014,34(1):89-90. 被引量:8
  • 2胡亚美,江载芳,申昆玲,等.诸福棠实用儿科学[M].8版.北京:人民卫生出版社,2015:916-919.
  • 3Dimitriades V R,Brown A G,Gedalia A.Kawasaki disease:pathophysiology,clinical manifestations and management[J].Curr Rheumatol Rep,2014,16(6):423-426.
  • 4Kumar R K,Tandon R.Rheumatic fever&:rheumatic heart disease:the last 50 years[J].Indian J Med Res,2013,137(4):643-658.
  • 5Korematsu S,Ohta Y,Tamai N,et al.Cell distribution differences of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in patients with Kawasaki disease[J].Pediatr Infect Dis J,2012,31(9):973-974.
  • 6Visse R,Hideaki N.Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure,function,and biochemistry[J].Circ Res,2003,92(8):827-839.
  • 7Brew K,Dinakarpandian D,Nagase H.Tissue inhibitors of metalloproteinases:evolution,structure and function[J].Biochim Biophys Acta,2000,1477(1-2):267-283.
  • 8Ravi A,Garg P,Sitaraman S V.Matrix metalloproteinases in inflammatory bowel disease:boon or a baine[J].Inflamm Bowel Dis,2007,13(1):97-107.
  • 9Opdenakker G,Van den Steen P E,Dubois B,et al.Gelatinase B functions as regulator and effector in leukocyte biology[J].J Leukoc Biol,2001,69(6):851-859.
  • 10Kalela A,Ponnio M,Koivu T A,et al.Association of serum sialic acid and MMP-9 with lipids and inflammatory markers[J].Eur J Clin Invest,2000,30(2):99-104.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部